Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral GCP + Nivolumab for Recurrent Head and Neck Cancer
NCT05835804Phase 2Not yet recruiting
- Sponsor
- CHU Amiens-Picardie
- Start
- Nov 2025
- Primary completion
- Apr 2026
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, carboplatin and Paclitaxel Micelles for Injection in squamous cell carcinoma of the head and neck (HNSCC), sponsored by CHU Amiens-Picardie. Primary endpoint: Local response rate according to RECIST criteria at 3 years. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
gemcitabinecarboplatinPaclitaxel Micelles for Injection
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT05835804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05835804.